Ads
related to: clindamycin half life chart of drugs for children adults
Search results
Results From The WOW.Com Content Network
Clindamycin is a lincosamide antibiotic medication used for the treatment of a number of bacterial infections, including osteomyelitis (bone) or joint infections, pelvic inflammatory disease, strep throat, pneumonia, acute otitis media (middle ear infections), and endocarditis. [5]
Clindamycin: Cleocin: Serious staph-, pneumo-, and streptococcal infections in penicillin-allergic patients, also anaerobic infections; clindamycin topically for acne: Possible C. difficile-related pseudomembranous enterocolitis: Binds to 50S subunit of bacterial ribosomal RNA thereby inhibiting protein synthesis. Lincomycin: Lincocin ...
Some adults also experience teeth discoloration (mild grey hue) after use. They are, however, safe to use in the first 18 weeks of pregnancy. [ 13 ] [ 14 ] Some patients taking tetracyclines require medical supervision because they can cause steatosis and liver toxicity .
Clearance of linezolid varies with age and gender; it is fastest in children (which accounts for the shorter half-life), and appears to be 20% lower in women than in men. [8] [105] [106] There is a strong correlation between linezolid clearance and creatinine clearance. [107]
Quinolone antibiotics constitute a large group of broad-spectrum bacteriocidals that share a bicyclic core structure related to the substance 4-quinolone. [1] They are used in human and veterinary medicine to treat bacterial infections, as well as in animal husbandry, specifically poultry production.
Sulfadimethoxine (or sulphadimethoxine, trade names Di-Methox or Albon) is a long-lasting sulfonamide antimicrobial medication used in veterinary medicine. It is used to treat many infections, including respiratory, urinary tract, enteric, and soft tissue infections [3] and can be given as a standalone or combined with ormetoprim to broaden the target range. [2]
The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl: 10665/259481. ISBN 978-92-4-121015-7. ISSN 0512-3054. WHO technical report series; no. 1006.
A separate list for children up to 12 years of age, known as the WHO Model List of Essential Medicines for Children (EMLc), was created in 2007 and is in its 9th edition. [ 10 ] [ 21 ] [ 22 ] [ 23 ] It was created to make sure that the needs of children were systematically considered such as availability of proper formulations .